drugset
drugset / Trial / NCT04118127

A Clinical Pharmacology Trial of Brexpiprazole Once-weekly (QW) Formulation Administered as Single and Multiple Oral Doses

NCT04118127 ↗

Phase 1 Completed 73 enrolled Otsuka Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the pharmacokinetics (PK), tolerability, and safety of brexpiprazole QW formulation administered as single and multiple doses in patients with schizophrenia.

Timeline

Start
2019-10-17
Primary completion
2021-02-16
Completion
2021-03-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Brexpiprazole Small molecule 2 mg Oral

Indications

schizophrenia